Result of Annual General Meeting

AI SummaryClose X

Allergy Therapeutics plc announced that all resolutions proposed at its 2026 Annual General Meeting were passed by shareholders, with overwhelming support for the approval of the 2025 accounts, directors' remuneration report, director elections and re-elections, auditor re-appointment, and authorities for share allotment. Specifically, Resolution 1, approving the 2025 Accounts, received 5,820,380,278 votes for, representing 99.99% of the votes cast, with 94.78% of the issued share capital participating. Similarly, resolutions concerning director appointments and share allotment authorities also saw very high percentages of approval, indicating strong shareholder confidence.

Disclaimer*

UK 100

Latest directors dealings